NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Source: PRnewswire
DOXA Platform Expansion: NLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, focusing on small molecules that enhance arousal stability, cognition, and neuroprotection.
Lead Compound AEX-635: AEX-635, a key compound in the DOXA series, targets Multidrug Resistance-Associated Protein 1 (MRP1) to improve neuroprotective effects and drug bioavailability in conditions like Parkinson's disease.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
